Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials.

ABSTRACT:

Background

Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objective was to determine the prevalence of DDIs involving study medications in subjects enrolling in National Clinical Trials Network (NCTN) clinical trials at a single institution. DDIs were evaluated based on study protocol recommendations for concomitant medication use (i.e. exclude, avoid or use caution), screening via DDI tool, and pharmacist review.

Methods

Subjects enrolled in NCTN trials of commercially available agents between January 2013 and August 2017 were included if a complete medication list was available. Complete med

SUBMITTER: Marcath LA 

PROVIDER: S-EPMC6249716 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature